Allianz Asset Management Gmb H Travere Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$20.94 - $30.01 $958,905 - $1.37 Million	45,793 Added 71.87%	109,513 $2.65 Million
Q1 2022 May 13, 2022	BUY	$23.61 - $30.6 $92,079 - $119,340	3,900 Added 6.52%	63,720 $1.64 Million
Q4 2021 Feb 11, 2022	BUY	$24.34 - $31.17 $1.46 Million - $1.86 Million	59,820 New	59,820 $1.85 Million
Q2 2021 Aug 16, 2021	SELL	$14.11 - $26.4 $206,499 - $386,364	-14,635 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$23.37 - $31.77 $1.61 Million - $2.19 Million	-68,985 Reduced 82.5%	14,635 $365,000
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $1.6 Million - $2.33 Million	83,620 New	83,620 $2.28 Million

192

84.5M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.